Arrowhead Pharmaceuticals, Inc.

Stocks

ARWR

US04280A1007

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-31 EDT			5-day change	1st Jan Change
84.65 ^USD	-3.06%		-1.11%	+27.50%

07-30	B. Riley Adjusts Arrowhead Pharmaceuticals Price Target to $123 From $101, Maintains Buy Rating	MT
07-29	RBC Raises Price Target on Arrowhead Pharmaceuticals to $100 From $87, Keeps Outperform, Speculative Risk	MT

Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call

Published on 06/29/2026 at 01:20 pm EDT - Modified on 07/03/2026 at 05:21 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, everyone, and welcome to Part 1 of Arrowhead Pharmaceuticals' 2026 Summer Series of R&D webinars. [Operator Instructions] As a reminder,

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

Latest news about Arrowhead Pharmaceuticals, Inc.

07-30	B. Riley Adjusts Arrowhead Pharmaceuticals Price Target to $123 From $101, Maintains Buy Rating	MT
07-29	RBC Raises Price Target on Arrowhead Pharmaceuticals to $100 From $87, Keeps Outperform, Speculative Risk	MT
07-27	Arrowhead Pharmaceuticals Completes Enrollment In Global Phase 3 Yosemite Study Of Zodasiran For The Treatment Of Homozygous Familial Hypercholesterolemia	CI
07-27	Arrowhead Completes Enrollment in Phase 3 Study of Treatment for Homozygous Familial Hypercholesterolemia	MT
07-23	Chardan Raises Price Target on Arrowhead Pharmaceuticals to $115 From $90, Keeps Buy Rating	MT
07-22	Arrowhead Pharmaceuticals Shares Rise After Phase 3 Trials of Plozasiran Meets Primary, Secondary Endpoints	MT
07-22	Top Midday Gainers	MT
07-22	Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 And SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia	CI
07-14	Biogen's Alzheimer's drug lowers toxic protein, but results were mixed	RE
07-14	Stifel Initiates Arrowhead Pharmaceuticals at Buy With $98 Price Target	MT
06-29	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Index	CI
06-29	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Value Benchmark	CI
06-29	Arrowhead Pharmaceuticals, Inc. - Special Call
06-29	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Growth Benchmark	CI
06-29	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Growth Benchmark	CI